Recent Updates
Recently added Catalysts

Epoetin alfa DT

Phase 3

Chronic Kidney Disease | Small molecule | Nephrology |Amgen Inc.|Last Updated: Feb 19, 2010

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment580

FDA Designations

No designations recorded

Clinical trial landscape

Epoetin alfa DT · 1 trial · 1 indication

Phase 3 1
NCT00156949EPO Deep Tank in Dialysis SubjectsChronic Kidney Disease
COMPLETED580 Analytics
PHASE3COMPLETED
EPO Deep Tank in Dialysis Subjects
Chronic Kidney DiseaseUnlock trial analytics

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Epoetin alfa DTEXPERIMENTAL -

Interventions

NameTypeDescription
Epoetin alfa DTDRUGReceive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: - ≥ 18 years of age - Receiving hemodialysis or peritoneal dialysis - Baseline Hb between 11.0 g/dL and 13.0 g/dL - Currently receiving Epoetin alfa RB ie. EPOGEN or PROCRIT - Transferrin saturation (Tsat) \>15.0% Exclusion Criteria: - Currently receiving or ever received treatme...

Unlock Eligibility Criteria